对于ST段升高肌肉梗塞的初级皮肤冠状动脉干预后的死亡率趋势
Pernille Gro Thrane1, Kevin Kris Warnakula Olesen1, Troels Thim2
1Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Journal of the American College of Cardiology
|August 30, 2023
概括
在丹麦,2003年至2018年期间,ST升高心肌梗塞 (STEMI) 后的死亡率显著下降. 生存率的最大改善发生在初级穿皮冠状动脉干预 (pPCI) 后的30天内.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 观察性研究表明,ST升高心肌梗塞 (STEMI) 在2006年至2010年期间的死亡率稳定.
- 自2003年以来,初级穿皮冠状动脉干预 (PCI) 已成为丹麦西部的标准再输注策略.
研究的目的:
- 分析STEMI后1年,30天和31-365天死亡率的时间趋势.
- 评估国家初级PCI战略对STEMI患者存活率的影响.
主要方法:
- 利用西丹麦心脏注册表来识别接受STEMI (2003-2018) 初级PCI的患者.
- 根据pPCI年份,将19,613名患者分为四个时间间隔.
- 通过使用丹麦国家卫生登记册,对患者进行了一年的跟踪.
主要成果:
- 一年死亡率从10.8% (2003年至2006年) 降至7.7% (2015年至2018年).
- 死亡率的最显著降低是在前30天内观察到的 (2.3%绝对降低).
- 在31至365天期间,死亡率的减少为1.0%.
结论:
- 丹麦全面实施的pPCI战略使得从2003年到2018年,一年内STEMI死亡率大幅下降.
- 大多数死亡率降低发生在pPCI后的30天内.
- 优化对接受pPCI的STEMI患者的早期治疗可以显著提高生存率.
更多相关视频
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
24.3K
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
相关概念视频
01:30Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
01:28Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
01:30Acute Coronary Syndrome III: Diagnostic Studies
10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
20
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
201
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
201